Merck announced on Monday that it has raised its expectations for new growth drivers, projecting that revenue from these new businesses will reach $70 billion by the mid-2030s. The company is accelerating the launch of more drugs to address the impending competition for its blockbuster cancer treatment, Keytruda.
The company now anticipates that cardiometabolic and respiratory treatments will generate approximately $20 billion in sales, up from a previous estimate of $15 billion, while infectious disease drugs are expected to contribute about $15 billion, higher than the prior estimate of $5 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments